AEON Biopharma, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from AEON Biopharma, Inc.'s yearly results (2021–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Debt, after subtracting cash, is 2.8 times its market value (net debt). Lower than 98% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-68.7×Operating cash was negative last year, while some debt falls due within a year.
Lower than 78% of Healthcare companies in United States.
Cash Cushion Ratio
2.8× debtDebt, after subtracting cash, is 2.8 times its market value (net debt).
Lower than 98% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (8)
AEON Biopharma, Inc. made a loss over the last year. AEON Biopharma, Inc. owes $3.60 for every $1 it owns. AEON Biopharma, Inc. made a loss in the year to Dec 2025, after a profit the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossAEON Biopharma, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-0.76AEON Biopharma, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$12 MThe total market value of all of AEON Biopharma, Inc.'s shares at today's price (share price × number of shares), smaller than 86% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
NegativeAEON Biopharma, Inc.'s net worth is negative ($15 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
3.60×AEON Biopharma, Inc. owes $3.60 for every $1 it owns, so it owes more than it owns, higher than almost all Healthcare companies in United States.
Dividend yield
NoneAEON Biopharma, Inc. does not currently pay a dividend.
Profit growth
LossAEON Biopharma, Inc. made a loss in the year to Dec 2025, after a profit the year before.
Cash vs debt
Net debtAEON Biopharma, Inc. had $33 M more debt than cash (net debt) at Dec 2025.
Questions
How much does AEON Biopharma, Inc. owe compared with what it owns?
AEON Biopharma, Inc. owes $3.60 for every $1 it owns, so it owes more than it owns, higher than almost all Healthcare companies in United States.
Does AEON Biopharma, Inc. pay a dividend?
No. AEON Biopharma, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.